The Convergent Treatment Strategy for AF
The Convergent procedure is a hybrid approach involving collaboration between a cardiac electrophysiologist and a cardiac surgeon.
The goal of the procedure is to return your heart back to normal sinus rhythm. The procedure is called hybrid as it is a collaboration between a specialist Electrophysiologist (EP) and Cardiac surgeon. EP leads the team to identify appropriate candidates who will benefit from the procedure.
The procedure has two stages. The first stage is minimal invasive surgery which is performed by the cardiac surgeon and the second stage is mapping and catheter ablation performed by EP.
The aim of the procedure is to ablate areas of the heart which are considered to be the source of AF. Radiofrequency is used as an energy to ablate, and create scar tissue in the focused area of the heart to ablate/interrupt AF circuits without causing any significant long-term side effects.
The Convergent treatment has an established track record with over 9000 procedures performed in the US and Europe.
Who is considered and why?
In the vast majority of patients with paroxysmal AF and a structurally normal heart, catheter ablation using radiofrequency energy (focused heat) only targeting the pulmonary veins (Pulmonary Vein Isolation or PVI) will provide an excellent suppression of AF. This is done by a cardiologist (cardiac electrophysiologist) and in most cases only requires an overnight stay in hospital. When this is successful the patient experiences an improvement in quality of life as a result of symptom control and avoids the need for anti-arrhythmic medication.
Convergent is considered when we suspect that AF is being initiated and maintained by diseased areas outside of the pulmonary veins. Most patients considered for Convergent will have persistent AF (AF that lasts continuously for more than 7 days) or will have failed previous attempts at PVI procedures. An electrophysiologist who has experience with Convergent identifies patients who are likely to benefit from the hybrid procedure. These patients generally represent the ‘difficult end of the spectrum of AF’ usually because they have AF sources separate or distant from the pulmonary veins. Not all patients who have persistent AF are candidates for this procedure.
What is the difference with catheter ablation?
Convergent is a significantly more aggressive ablation strategy than standard catheter ablation. It requires a close collaboration between two medical specialists and their respective teams; A cardiothoracic surgeon and a cardiac electrophysiologist. The surgeon will perform the surgical ablation which is the first part of the treatment and then six months later the cardiac electrophysiologist will perform a catheter mapping and ablation procedure accessing the heart using catheters inserted at the right groin.
Fundamentally, cardiothoracic surgeons are able to perform minimally invasive ‘thoracoscopic’ procedures from the outside of the heart, while cardiac electrophysiologists perform minimally invasive procedures using catheters placed within the heart itself. This approach allows for maximum ablation of the posterior left atrial wall resulting in debulking of AF sources.
The surgeon performs a thoracoscopic surgical ablation which requires the use of a specially engineered ablation tool and delivery system. Thoracoscopic surgical ablation is performed on the beating heart with small incisions rather than entirely opening the chest wall and stopping the heart from beating. This significantly reduces the risk, and results in a more rapid recovery than open heart surgery.
The surgical ablation tool has a much larger working surface than an ablation catheter and, using the same radiofrequency energy as catheter ablation, efficiently ablates a greater surface area of atrial tissue. In addition, the latest design of surgical tools allows for the radiofrequency energy to be directed only to the focused area of the heart while protecting the structures around it. This design helps prevent injury to the oesophagus (food pipe) which is highly sensitive to heat. This avoids a nasty complication called atrial esophageal fistula.
During the Convergent procedure and immediately after the surgical ablation, an additional procedure is performed to occlude and isolate the left atrial appendage. The left atrial appendage is a little pouch originating from the left atrium. It is thought to be the source of 90% of clots in patients with atrial fibrillation increasing the risk of stroke. Your left atrial appendage will be occluded with a device known as Atriclip PRO2. This serves two important functions:
- Stroke reduction – the majority of blood clots (>95%) leading to AF strokes originate from the left atrial appendage
- AF reduction – the appendage muscle tissue becomes strangulated because the pressure of the AtriClip blocks the nourishing blood flow and eventually the tissue beyond the Atriclip dies. This removes another potential non-pulmonary vein electrical source of AF as the left atrial appendage is a well recognised secondary source of AF triggers.
Each patient has different anatomy and some areas of the left atrium cannot be reached during the surgical part of the procedure. For this reason at 2-3 months post-surgery, the cardiac electrophysiologist will perform an extensive electrical mapping and ‘touch up ablation’ of the left atrium using specialised mapping tools and 3 dimensional electrical mapping. The pulmonary veins are also checked and re-ablated if necessary during this second component.